Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral CoV2-OGEN1 in Healthy Subjects
NCT04893512Phase 1Completed
- Sponsor
- Syneos Health
- Start
- Jun 2021
- Primary completion
- Nov 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CoV2-OGEN1 in coronavirus disease 2019 (COVID-19), sponsored by Syneos Health. Primary endpoint: Adverse Events at 6 months. Started Jun 2021; status: completed.
02
Drugs
CoV2-OGEN1
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04893512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04893512.